A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This project is a key clinical research project approved by the Clinical Research Center of
the First Affiliated Hospital of Xi'an Jiaotong University. Tyrosine kinase inhibitors (TKI)
combined with intensive chemotherapy has markedly improved the outcomes of
philadelpha-positive lymphoblastic leukemia (Ph+ ALL). However, a considerable proportion of
patients failed to complete the intended chemotherapy and some even died early. The optimal
balance between the intensity of chemotherapy and safety should be explored. In this study,
Ph+ ALL patients who achieve complete remission (CR) after VP regimen (vincristine and
prednisone) plus dasatinib as induction are enrolled and then the participants will receive
different consolidation chemotherapy. Patients in the group A will continue to use VP regimen
plus dasatinib, while the group B receives hyper-CVAD/methotrexate-cytarabine regimen plus
dasatinib. The measurable residual disease (MRD), CR, adverse effects (AE), overall survival
(OS) and disease free survival (DFS) will be observed to determine the proper consolidation
chemotherapy regimen.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University